Contrast-enhanced transrectal ultrasonography in guiding prostate biopsy for diagnosis of prostate cancer
10.13929/j.issn.1672-8475.2020.02.008
- Author:
Xiaoqiu LIANG
1
Author Information
1. Department of Medical Ultrasound, Chengdu Fifth People's Hospital
- Publication Type:Journal Article
- Keywords:
Prostate-specific antigen;
Prostatic neoplasms;
Rectum;
Ultrasonography
- From:
Chinese Journal of Interventional Imaging and Therapy
2020;17(2):93-97
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the value of contrast-enhanced transrectal ultrasonography (CETRUS) in guiding prostate biopsy for diagnosis of prostate cancer (PCa). Methods Transrectal ultrasound (TRUS), CETRUS and transrectal prostate biopsy were performed in 79 patients with suspected PCa. The diagnosed efficiency of TRUS, CETRUS and TRUS combined CETRUS were compared and taken pathology results as diagnostic criteria. Results Among 79 patients, PCa was pathologically diagnosed in 36 cases, while benign prostatic hyperplasia was diagnosed in 43 cases. Pathology results proved PCa in 30 patients among 35 patients with abnormal CETRUS, and the sensitivity, specificity and accuracy of CETRUS for diagnosing PCa was 83.33% (30/36), 88.37% (38/43) and 86.08% (68/79), respectively. Pathology results proved PCa in 24 patients among 39 patients with abnormal TRUS, and the sensitivity, specificity and accuracy of TRUS for diagnosing PCa was 66.67% (24/36), 65.12% (28/43) and 65.82% (52/79), respectively. Thirty cases of PCa were diagnosed with TRUS combined CETRUS, and the sensitivity, specificity and accuracy was 83.33% (30/36), 72.09% (31/43) and 77.22% (61/79), respectively. ROC curve analysis showed that the AUC of TRUS, CETRUS and TRUS combined CETRUS was 0.740, 0.859 and 0.777,respectvely. The diagnostic efficiency of CETRUS was higher than that of TRUS (Z=2.371, P=0.018) and TRUS combined CETRUS (Z=2.858, P=0.004). Conclusion: The diagnostic efficiency of CETRUS is high for guiding transrectal prostate biopsy to diagnose PCa.
